In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT +2.13%), Johnson & Johnson (JNJ +3.00%), Sanofi (SNY +1.25%), Pfizer (PFE +1.28%), and Merck (MRK -0.49%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.